Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Int J Cancer. 2016 Aug 18;139(11):2519–2528. doi: 10.1002/ijc.30372

Table 3.

Comparison of Cases Given AVT and Cases Never Given AVT.

Cases given AVT
No. of patients (%)
Cases never given
No. of patients (%)
p
Total number of patients N=26 N=40
Demographics
 Age, years [median (IQR)] 58 (54 - 65) 59 (53 - 63) 0.89
 Gender, male 21/26 (81) 26/40 (65) 0.16
 Race, white 19/26 (73) 25/39 (64) 0.44
DLBCL characteristics
 De novo DLBCL 21/26 (81) 28/40 (70) 0.32
 Immunohistochemistry, GCB 11/19 (58) 16/29 (55) 0.85
 Ann Arbor, stage 3-4 19/25 (76) 33/40 (83) 0.52
 Extranodal involvement 20/26 (77) 31/40 (78) 0.95
 Presence of B symptoms 8/26 (31) 12/37 (32) 0.88
 ECOG score, 2-4 7/23 (30) 10/32 (31) 0.94
 IPI score, high risk 7/19 (37) 5/31 (16) 0.17
 Bone marrow biopsy, positive 8/26 (31) 15/38 (40) 0.47
 LDH level, U/L [median (IQR)] 631 (522 - 943) 657 (499 - 1075) 0.66
Infectious characteristics
 HCV genotype 1 13/21 (62) 27/34 (79) 0.15
 HbsAg, positive 0 2/40 (3) 0.51
 HbcAb, positive 12/26 (46) 18/40 (45) 0.92
 HBV DNA, detected 2/10 (20) 2/17 (12) 0.61
Hepatic characteristics
 Cirrhosis 5/26 (19) 10/40 (25) 0.58
 Child Pugh score A 3/5 (60) 4/10 (40) 0.61
 Portal hypertension 4/5 (80) 9/10 (90) 0.90
 METAVIR, stage 3-4 9/16 (56) 2/10 (20) 0.10
Oncologic treatment
 First line chemotherapy, RCHOP 20/26 (77) 25/29 (86) 0.27
 HCT 6/26 (23) 7/38 (18) 0.64
 Radiotherapy 8/26 (31) 11/38 (29) 0.87
 Received further chemotherapy 12/26 (46) 16/37 (43) 0.81
 Second line chemotherapy, RICE 8/13 (62) 10/15 (67) >0.99
Oncologic outcomes
 PFS, months [median (IQR)] 27 (7 - 45) 10 (4 - 42) 0.18
 DFS, months [median (IQR)] 24 (3 - 41) 6 (0 - 34) 0.10
 OS, months [median (IQR)] 39 (26 - 56) 16 (6 - 41) 0.02

AVT indicates antiviral therapy; IQR, interquartile range; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; HCV, hepatitis C virus; HbsAg, hepatitis b surface antigen; HbcAb, hepatitis b core antibody; HBV, hepatitis B virus; R-CHOP, rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone; HCT, hematopoietic stem cell transplantation; R-ICE, rituximab-ifosfamide, carboplatin, and etoposide; PFS, progression free survival; DFS, disease free survival; and OS, overall survival.